Isabella Caicedo-Ortiz

Isabella Caicedo-Ortiz

Auto-generated profile, based on publicly available information

Isabella Caicedo-Ortiz

Clínica Imbanaco, Cali, Colombia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
RORocío Orduz
Rocío Orduz
JRJavier Rendón
Javier Rendón
MRMartha Romero
Martha Romero
SQSandra Quijano
Sandra Quijano
ICIsabella Caicedo-Ortiz
Isabella Caicedo-Ortiz
CCCarlos Alberto Castro
Carlos Alberto Castro
The hematolymphoid neoplasms are considered to be of high cost and have an impact on quality of life, for this reason the use of diagnostic and tests for follow-up such as Measurable Residual Disease (MRD) continues to be a tool to determine prognoses, considering new technologies and the importance of standardizing processing. Objective: To structure a series of considerations by common agreement of experts about Measurable Residual Disease in 5 hematological pathologies, in the Colombian context. Methods: A formal consensus of experts, mixed (Delphi/Nominal), was made from 23 context questions related to Measurable Residual Disease in 5 hematological pathologies. 2 qualifying rounds and a virtual nominal meeting were held. The information was analyzed in STATA 13. Results: 23 questions related to the diagnosis of Measurable Residual Disease in 5 hematological pathologies were constructed in the context of its use in Colombia. 17 health professionals (pathology and bacteriology) experts in Measurable Residual Disease by flow cytometry from Bogotá, Medellín, Cali, Bucaramanga, Cartagena, Rionegro, Barranquilla and Cúcuta participated and it was leading by the Colombian Association of Hematology and Oncology (ACHO). Conclusions: 23 considerations were defined to guide the use of flow cytometry for Measurable Residual Disease in 5 hematological pathologies, as well as to make a diagnosis of the context of this test in Colombia. Finally, this consensus aims to standardize this technique as well standardize clinical conducts between hemato-oncologists hoping to improve the decisions that are taken because this measurement in order to improve health´s patients.